As global markets navigate a complex landscape marked by busy earnings reports and economic data, the technology sector remains a focal point, with indices such as the Nasdaq Composite experiencing ...

On Thursday, the EMA (European Medicines Agency) approved the long-awaited treatment after initially blocking it in July, ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...

French drugmaker Ipsen (Euronext: IPN) announced late-breaking data for Iqirvo (elafibranor 80mg tablets) from an interim ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...

Pamela, 73, has lived with Alzheimer’s for two years. David is an Alzheimer’s advocate. More medications are emerging to ...